查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1632594

全球生技藥品監管提交外包市場：市場規模、佔有率和趨勢分析（按服務、按階段、按方式、按服務和階段、按方式和服務、按地區、按細分市場，2025-2030 年）

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service (Regulatory Consulting), By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

生技藥品監管適用性外包市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，全球生技藥品監管應用外包市場預計到 2030 年將達到 36.9 億美元，2025 年至 2030 年的複合年成長率為 9.06%。

生物製藥公司的全球化是推動市場整體需求的主要成長要素之一。亞太地區、拉丁美洲、中東和非洲的新興市場具有較低的產品開發和製造成本、優惠的稅收制度、相對低成本的技術純熟勞工和良好監管的市場。上述因素使得該區域市場對生物製藥公司來說具有外包和擴張的吸引力，刺激了對監管服務的需求。此外，新興國家擁有 EMA 和/或 FDA 批准的設施預計將吸引更多的外國投資，這反過來又會增加對法律代表和監管諮詢服務等監管服務的需求。

新興國家正在進行的臨床實驗的數量大幅增加。這是因為與美國等新興經濟體相比，這些地區擁有熟練勞動力、先進技術和基礎設施，且成本相對較低，預計將刺激這些地區對臨床實驗申請和產品註冊等監管服務的需求。新興國家佔全球臨床實驗申請總量的30.0%以上，預計未來幾年這一佔有率將會增加，進而促進市場的成長。

一些生物製藥公司正專注於其核心競爭力，並外包非核心功能以提高生產力和業務效率。這些公司在遵守國際法規方面面臨許多挑戰，這可能既耗時又繁瑣。因此，在可行的時間內以合理的成本將新型分子推向市場的競爭可能會推動對服務提供者的需求。此外，許多不具備內部能力的中小型生物製藥公司正在轉向外包其監管業務，這估計將對行業進步產生積極影響。

生物相似藥、孤兒藥、個人化藥物和自適應試驗設計市場的成長預計將推動這些領域對監管業務的需求。隨著多家公司向新領域擴張，對具有監管經驗和遵守法規要求的熟練服務供應商的需求也日益增加。政府資助的罕見疾病藥物研發大幅增加，尤其是在新興經濟體。 Simulect、 Vectibix、 Mircera和 Kineret 等生技藥品的專利到期，增加了對生物相似藥的需求和發展，從而增加了該領域對監管服務的需求。

生技藥品監管適用性外包市場：分析概述

  • 2024 年，監管文件撰寫和出版領域佔據了最大的市場佔有率。該領域的高速成長是由於生技藥品越來越複雜，需要準確全面的文件記錄，嚴格的國際監管要求要求全面提交，以及需要專業知識來確保合規性。基因療法和生物學名藥等生技藥品的快速創新步伐需要對不斷發展的法規有最新的了解，這有望推動整體市場的成長。
  • 臨床階段部分將在 2024 年佔據最大佔有率。該部門收益的強勁成長歸功於過去幾年臨床實驗報名數量的增加。
  • 單株抗體 (mAb) 部分在 2024 年佔據了最大的收益佔有率。該領域的成長得益於 mAb 技術的快速進步，包括新穎的遞送方法和治療目標，這需要更新和精確的監管策略，從而帶來市場的整體成長潛力。
  • 亞太地區生技藥品監管申請外包市場預計將在 2024 年佔據最大的收益佔有率，為 40.94%，並在預測期內以最快的複合年成長率成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章生技藥品監管適用性外包市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 技術進步
    • 使用現有和新技術以及推薦工具
    • 區分內部工具和廣泛使用的工具
    • 關鍵技術支柱
    • 巨量資料與分析
    • RTP、文字處理、分析
    • 音訊和視訊分析
    • 物聯網 (IoT)
    • 人工智慧工具
  • 定價模式分析
  • 臨床實驗數量分析（2024 年）
    • 各地區臨床實驗總數（2024 年）
    • 各階段臨床實驗總數（2024 年）
    • 依研究設計分類的臨床實驗總數（2024 年）
    • 按主要治療領域分類的臨床實驗總數（2024 年）
  • 市場分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章生技藥品監管適用性外包市場估計與趨勢分析（按服務）

  • 細分儀表板
  • 全球生技藥品監管適用性外包市場：趨勢分析
  • 全球生技藥品監管適用性外包市場：按服務類型分類的市場規模和趨勢分析（2018-2030 年）
    • 監理諮詢
    • 法律代表
    • 監管文件的撰寫和發布
    • 產品註冊和臨床實驗申請
    • 監管提交
    • 監管業務
    • 其他服務

第 5 章生技藥品監管適用性外包市場估計與趨勢分析（分階段）

  • 細分儀表板
  • 全球生技藥品監管適用性外包市場：趨勢分析
  • 全球生技藥品監管適用性外包市場：市場規模與趨勢分析（按階段分類）（2018-2030 年）
    • 臨床前
    • 臨床

第6章生技藥品監管適用性外包市場估計與趨勢分析

  • 細分儀表板
  • 全球生技藥品監管適用性外包市場：趨勢分析
  • 全球生技藥品監管適用性外包市場：按模式分類的市場規模和趨勢分析（2018-2030 年）
  • 單株抗體（mAb）
  • 重組蛋白
  • 疫苗
  • 細胞和基因治療
  • 生物相似藥
  • 其他

第 7生技藥品。

  • 細分儀表板
  • 全球生技藥品監管適用性外包市場：趨勢分析
  • 全球生技藥品監管適用性外包市場：按階段和服務分類的市場規模和趨勢分析（2018-2030 年）
    • 臨床前
    • 臨床

第 8 章生技藥品監管適用性外包市場估計和趨勢分析（按階段和模式）

  • 細分儀表板
  • 全球生技藥品監管適用性外包市場：趨勢分析
  • 全球生技藥品監管適用性外包市場：市場規模和趨勢分析（按模式和階段）（2018-2030 年）
    • 臨床前
    • 臨床

第 9 章生技藥品監管適用性外包市場估計和趨勢分析（按服務和模式）

  • 細分儀表板
  • 全球生技藥品監管適用性外包市場：趨勢分析
  • 全球生技藥品監管適用性外包市場：市場規模和趨勢分析、按服務和模式（2018-2030 年）
    • 單株抗體（mAb）
    • 重組蛋白
    • 疫苗
    • 細胞和基因治療
    • 生物相似藥
    • 其他

第 10生技藥品。

  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章 競爭格局

  • 市場參與企業分類
    • 市場領導
    • 新興企業
  • 競爭市場佔有率/估值分析（2024 年）
  • 公司簡介
    • Lonza AG
    • Wuxi Apptec Inc.
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • Freyrsolutions
    • Catalent Inc.
    • Piramal Group
    • AGC Biologics
    • ICON Plc.
Product Code: GVR-4-68040-369-4

Biologics Regulatory Affairs Outsourcing Market Growth & Trends:

The global biologics regulatory affairs outsourcing market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 9.06% from 2025 to 2030, according to a new report by Grand View Research, Inc. Globalization of biopharmaceutical companies is one of the major growth drivers boosting overall market demand. Emerging markets of Asia Pacific, Latin America, and MEA regions offer low product development & manufacturing costs, tax benefits, and availability of skilled labor at relatively low costs with supportive regulations. The abovementioned factors have made the regional markets attractive prospects in terms of outsourcing and expansion for biopharmaceutical companies, thereby stimulating the demand for regulatory services. Furthermore, the presence of EMA- and/or FDA-approved facilities in emerging economies is anticipated to increase foreign investments in the country and the demand for regulatory services, such as legal representation and regulatory consulting services.

A significant increase has been witnessed in the number of clinical trials conducted in emerging economies. This can be attributed to the availability of skilled labor, advanced technologies, and infrastructure facilities at relatively lower costs than developed economies such as the U.S., which is expected to stimulate the demand for regulatory services such as clinical trial applications & product registrations in these regions. Emerging economies contribute to more than 30.0% of total clinical trial applications submitted across the globe, and the share is expected to increase over the coming years, contributing to market growth.

Several biopharmaceutical companies are focusing on their core competencies and outsourcing noncore functions to increase their productivity & operational efficiency. These companies face several challenges with regard to complying with global regulations, which can be a lengthy and tedious process. Thus, the race to launch a novel molecule in the market in a feasible timeline and at a reasonable cost will likely propel the demand for service providers. Furthermore, many small- and medium-scale biopharma companies lacking in-house capabilities are inclined towards outsourcing regulatory affairs, which is estimated to positively influence the industry's progression.

Growth in markets for biosimilars, orphan drugs, personalized medicines, adaptive trial designs, and others is projected to boost the demand for regulatory specialization in these areas. As several companies expand into new avenues, the increasing need for skilled service providers with experience in regulations leads to the necessity to comply with regulations. Government support, especially in developed economies, has significantly increased the development of orphan drugs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services in this segment.

Biologics Regulatory Affairs Outsourcing Market Report Highlights:

  • The regulatory writing & publishing segment held the largest market share in 2024. The high segment growth is owing to the increasing complexity of biologics requiring precise and comprehensive documentation, stringent global regulatory requirements demanding thorough submissions, and the need for specialized expertise to ensure compliance. The rapid pace of innovation in biologics, such as gene therapies and biosimilars, necessitates up-to-date knowledge of evolving regulations is anticipated overall market growth
  • The clinical phase segment accounted for the largest share in 2024. The high segmental revenue growth can be attributed to the increasing number of clinical trial registrations over the past few years
  • The monoclonal antibodies (mAbs) segment accounted for the largest revenue share in 2024. The segmental growth is owing to rapid advancements in mAb technology, including novel delivery methods and therapeutic targets, which require updated and precise regulatory strategies leading to overall market growth potential
  • The Asia Pacific biologics regulatory affairs outsourcing market held the largest revenue share of 40.94% in 2024 and is expected to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1:
    • 1.10.2. Objective - 2:
    • 1.10.3. Objective - 3:
    • 1.10.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biologics Regulatory Affairs Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Number of Clinical Trials
      • 3.2.1.2. Increasing Adoption of the Personalized Medicine and Novel Therapeutics
      • 3.2.1.3. Rising R&D Investment in the Healthcare Industry
      • 3.2.1.4. Advancements in the Regulatory Affairs Market
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Managing Relationships
  • 3.3. Technological Advancements
    • 3.3.1. Existing and Emerging Use of Technology and Preferred Tools
    • 3.3.2. Differentiating In-House Tools Vs Widely Available
    • 3.3.3. Key Technology Pillars
      • 3.3.3.1. Digital Transformation and Data Integrity
      • 3.3.3.2. Artificial Intelligence, Machine Learning/Automation
      • 3.3.3.3. Data Analysis and Predictive Modeling
      • 3.3.3.4. Automation of Routine Tasks
      • 3.3.3.5. Compliance Monitoring
      • 3.3.3.6. Discovery and Development
      • 3.3.3.7. Regulatory Guidelines Related to AI/ML
    • 3.3.4. Big Data and Analytics
    • 3.3.5. RTP, Text Processing and Analytics
    • 3.3.6. Speech and Video Analytics
    • 3.3.7. IoT (Internet Of Things)
    • 3.3.8. AI Tools
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2024
    • 3.5.1. Total Number of Clinical Trials, by Region (2024)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2024)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2024)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Biologics Regulatory Affairs Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 4.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
    • 4.3.1. Regulatory Consulting
      • 4.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.2. Strategy & Development Planning
        • 4.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.3. QA Consulting
        • 4.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.4. Agent Services
        • 4.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.5. Others
        • 4.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Legal Representation
      • 4.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Regulatory Writing & Publishing
      • 4.3.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Product Registration & Clinical Trial Applications
      • 4.3.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Regulatory Submissions
      • 4.3.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.6. Regulatory Operations
      • 4.3.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.7. Other Services
      • 4.3.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biologics Regulatory Affairs Outsourcing Market: Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 5.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
    • 5.3.1. Preclinical
      • 5.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 5.3.2. Clinical
      • 5.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.2. Phase I
        • 5.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.3. Phase II
        • 5.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.4. Phase III
        • 5.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.5. Phase IV
        • 5.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biologics Regulatory Affairs Outsourcing Market: Modality Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 6.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
  • 6.4. Monoclonal Antibodies (mAbs)
    • 6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.5. Recombinant Proteins
    • 6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.6. Vaccines
    • 6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.7. Cell & Gene Therapies
    • 6.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.8. Biosimilars
    • 6.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biologics Regulatory Affairs Outsourcing Market: Phase by Service Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 7.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Service, 2018 to 2030 (USD Million)
    • 7.3.1. Preclinical
      • 7.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.2. Regulatory Consulting
        • 7.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.3. Legal Representation
        • 7.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.4. Regulatory Writing & Publishing
        • 7.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.5. Product Registration & Clinical Trial Applications
        • 7.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.6. Regulatory Submissions
        • 7.3.1.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.7. Regulatory Operations
        • 7.3.1.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.8. Other Services
        • 7.3.1.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 7.3.2. Clinical
      • 7.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.2. Regulatory Consulting
        • 7.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.3. Legal Representation
        • 7.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.4. Regulatory Writing & Publishing
        • 7.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.5. Product Registration & Clinical Trial Applications
        • 7.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.6. Regulatory Submissions
        • 7.3.2.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.7. Regulatory Operations
        • 7.3.2.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.8. Other Services
        • 7.3.2.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biologics Regulatory Affairs Outsourcing Market: Phase by Modality Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 8.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Modality, 2018 to 2030 (USD Million)
    • 8.3.1. Preclinical
      • 8.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.2. Monoclonal Antibodies (mAbs)
        • 8.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.3. Recombinant Proteins
        • 8.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.4. Vaccines
        • 8.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.5. Cell & Gene Therapies
        • 8.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.6. Biosimilars
        • 8.3.1.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.7. Others
        • 8.3.1.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.3.2. Clinical
      • 8.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.2. Monoclonal Antibodies (mAbs)
        • 8.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.3. Recombinant Proteins
        • 8.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.4. Vaccines
        • 8.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.5. Cell & Gene Therapies
        • 8.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.6. Biosimilars
        • 8.3.2.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.7. Others
        • 8.3.2.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 9. Biologics Regulatory Affairs Outsourcing Market: Modality by Service Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 9.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Modality by Service, 2018 to 2030 (USD Million)
    • 9.3.1. Monoclonal Antibodies (mAbs)
      • 9.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.2. Regulatory Consulting
        • 9.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.3. Legal Representation
        • 9.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.4. Regulatory Writing & Publishing
        • 9.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.5. Product Registration & Clinical Trial Applications
        • 9.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.6. Regulatory Submissions
        • 9.3.1.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.7. Regulatory Operations
        • 9.3.1.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.8. Other Services
        • 9.3.1.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.2. Recombinant Proteins
      • 9.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.2. Regulatory Consulting
        • 9.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.3. Legal Representation
        • 9.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.4. Regulatory Writing & Publishing
        • 9.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.5. Product Registration & Clinical Trial Applications
        • 9.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.6. Regulatory Submissions
        • 9.3.2.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.7. Regulatory Operations
        • 9.3.2.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.8. Other Services
        • 9.3.2.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.3. Vaccines
      • 9.3.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.2. Regulatory Consulting
        • 9.3.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.3. Legal Representation
        • 9.3.3.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.4. Regulatory Writing & Publishing
        • 9.3.3.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.5. Product Registration & Clinical Trial Applications
        • 9.3.3.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.6. Regulatory Submissions
        • 9.3.3.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.7. Regulatory Operations
        • 9.3.3.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.8. Other Services
        • 9.3.3.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.4. Cell & Gene Therapies
      • 9.3.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.2. Regulatory Consulting
        • 9.3.4.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.3. Legal Representation
        • 9.3.4.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.4. Regulatory Writing & Publishing
        • 9.3.4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.5. Product Registration & Clinical Trial Applications
        • 9.3.4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.6. Regulatory Submissions
        • 9.3.4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.7. Regulatory Operations
        • 9.3.4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.8. Other Services
        • 9.3.4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.5. Biosimilars
      • 9.3.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.2. Regulatory Consulting
        • 9.3.5.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.3. Legal Representation
        • 9.3.5.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.4. Regulatory Writing & Publishing
        • 9.3.5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.5. Product Registration & Clinical Trial Applications
        • 9.3.5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.6. Regulatory Submissions
        • 9.3.5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.7. Regulatory Operations
        • 9.3.5.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.8. Other Services
        • 9.3.5.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.6. Others
      • 9.3.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.2. Regulatory Consulting
        • 9.3.6.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.3. Legal Representation
        • 9.3.6.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.4. Regulatory Writing & Publishing
        • 9.3.6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.5. Product Registration & Clinical Trial Applications
        • 9.3.6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.6. Regulatory Submissions
        • 9.3.6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.7. Regulatory Operations
        • 9.3.6.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.8. Other Services
        • 9.3.6.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 10. Biologics Regulatory Affairs Outsourcing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Framework
      • 10.5.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Framework
      • 10.5.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Framework
      • 10.5.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Framework
      • 10.5.5.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Framework
      • 10.5.6.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Framework
      • 10.5.7.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Framework
      • 10.5.8.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Framework
      • 10.5.9.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Framework
      • 10.6.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.3. Japan
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Framework
      • 10.6.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Framework
      • 10.6.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Framework
      • 10.6.5.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Framework
      • 10.6.6.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Framework
      • 10.6.7.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Framework
      • 10.7.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Framework
      • 10.7.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Framework
      • 10.8.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Framework
      • 10.8.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Framework
      • 10.8.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Framework
      • 10.8.5.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Competitive Market share/Assessment Analysis, 2024
  • 11.3. Company Profiles
    • 11.3.1. Lonza AG
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Wuxi Apptec Inc.
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Thermo Fisher Scientific Inc.
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Eurofins Scientific SE
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Freyrsolutions
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Catalent Inc.
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Piramal Group
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. AGC Biologics
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. ICON Plc.

List of Tables

  • Table. 1 List of Secondary Sources
  • Table. 2 List of Abbreviations
  • Table. 3 Global Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 4 Global Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 5 Global Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 6 Global Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 7 Global Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 8 Global Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 9 Global Biologics Regulatory Affairs Outsourcing, by Region, 2018 - 2030 (USD Million)
  • Table. 10 North America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 11 North America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 12 North America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 13 North America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 14 North America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 15 North America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 16 North America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 17 U.S. Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 18 U.S. Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 19 U.S. Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 20 U.S. Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 21 U.S. Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 22 U.S. Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 23 Canada Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 24 Canada Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 25 Canada Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 26 Canada Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 27 Canada Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 28 Canada Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 29 Mexico Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 30 Mexico Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 31 Mexico Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 32 Mexico Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 33 Mexico Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 34 Mexico Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 35 Europe Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 36 Europe Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 37 Europe Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 38 Europe Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 39 Europe Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 40 Europe Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 41 Europe Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 42 Germany Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 43 Germany Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 44 Germany Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 45 Germany Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 46 Germany Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 47 Germany Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 48 UK Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 49 UK Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 50 UK Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 51 UK Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 52 UK Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 53 UK Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 54 France Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 55 France Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 56 France Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 57 France Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 58 France Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 59 France Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 60 Italy Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 61 Italy Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 62 Italy Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 63 Italy Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 64 Italy Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 65 Italy Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 66 Spain Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 67 Spain Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 68 Spain Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 69 Spain Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 70 Spain Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 71 Spain Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 72 Denmark Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 73 Denmark Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 74 Denmark Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 75 Denmark Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 76 Denmark Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 77 Denmark Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 78 Sweden Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 79 Sweden Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 80 Sweden Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 81 Sweden Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 82 Sweden Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 83 Sweden Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 84 Norway Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 85 Norway Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 86 Norway Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 87 Norway Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 88 Norway Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 89 Norway Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 90 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 91 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 92 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 93 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 94 Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 95 Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 96 Asia Pacific Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 97 China Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 98 China Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 99 China Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 100 China Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 101 China Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 102 China Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 103 Japan Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 104 Japan Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 105 Japan Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 106 Japan Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 107 Japan Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 108 Japan Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 109 India Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 110 India Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 111 India Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 112 India Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 113 India Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 114 India Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 115 South Korea Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 116 South Korea Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 117 South Korea Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 118 South Korea Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 119 South Korea Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 120 South Korea Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 121 Australia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 122 Australia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 123 Australia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 124 Australia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 125 Australia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 126 Australia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 127 Thailand Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 128 Thailand Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 129 Thailand Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 130 Thailand Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 131 Thailand Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 132 Thailand Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 133 Latin America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 134 Latin America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 135 Latin America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 136 Latin America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 137 Latin America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 138 Latin America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 139 Latin America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 140 Brazil Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 141 Brazil Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 142 Brazil Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 143 Brazil Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 144 Brazil Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 145 Brazil Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 146 Argentina Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 147 Argentina Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 148 Argentina Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 149 Argentina Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 150 Argentina Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 151 Argentina Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 152 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 153 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 154 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 155 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 156 Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 157 Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 158 Middle East & Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 159 South Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 160 South Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 161 South Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 162 South Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 163 South Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 164 South Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 165 Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 166 Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 167 Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 168 Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 169 Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 170 Saudi Arabia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 171 UAE Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 172 UAE Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 173 UAE Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 174 UAE Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 175 UAE Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 176 UAE Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 177 Kuwait Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 178 Kuwait Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 179 Kuwait Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 180 Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 181 Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 182 Kuwait Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biologics Regulatory Affairs Outsourcing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biologics Regulatory Affairs Outsourcing, for Strategy & Development Planning, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biologics Regulatory Affairs Outsourcing, for QA Consulting, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biologics Regulatory Affairs Outsourcing, for Agent Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biologics Regulatory Affairs Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 18 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 19 Global Biologics Regulatory Affairs Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biologics Regulatory Affairs Outsourcing, for Preclinical, 2018 - 2030 (USD Million)
  • Fig. 23 Global Biologics Regulatory Affairs Outsourcing, for Clinical, 2018 - 2030 (USD Million)
  • Fig. 24 Global Biologics Regulatory Affairs Outsourcing, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biologics Regulatory Affairs Outsourcing, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biologics Regulatory Affairs Outsourcing, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 27 Global Biologics Regulatory Affairs Outsourcing, for Phase IV, 2018 - 2030 (USD Million)
  • Fig. 28 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 29 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 30 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 31 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 32 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 33 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 34 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Other Services, 2018 - 2030 (USD Million)
  • Fig. 35 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 36 Global Biologics Regulatory Affairs Outsourcing, for Clinical Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 37 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 38 Global Biologics Regulatory Affairs Outsourcing, for Clinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 39 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 40 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 41 Global Biologics Regulatory Affairs Outsourcing, for Clinical Other Services, 2018 - 2030 (USD Million)
  • Fig. 42 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 43 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 44 Global Biologics Regulatory Affairs Outsourcing, for Vaccines, 2018 - 2030 (USD Million)
  • Fig. 45 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 46 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 47 Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 48 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 49 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 50 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Vaccines, 2018 - 2030 (USD Million)
  • Fig. 51 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 52 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 53 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Others, 2018 - 2030 (USD Million)
  • Fig. 54 Global Biologics Regulatory Affairs Outsourcing, for Clinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 55 Global Biologics Regulatory Affairs Outsourcing, for Clinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 56 Global Biologics Regulatory Affairs Outsourcing, for Clinical Vaccines, 2018 - 2030 (USD Million)
  • Fig. 57 Global Biologics Regulatory Affairs Outsourcing, for Clinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 58 Global Biologics Regulatory Affairs Outsourcing, for Clinical Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 59 Global Biologics Regulatory Affairs Outsourcing, for Clinical Others, 2018 - 2030 (USD Million)
  • Fig. 60 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 61 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 62 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 63 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 64 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 65 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 66 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Other Services, 2018 - 2030 (USD Million)
  • Fig. 67 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 68 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 69 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 70 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 71 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 72 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 73 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Other Services, 2018 - 2030 (USD Million)
  • Fig. 74 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 75 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 76 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 77 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 78 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 79 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 80 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Other Services, 2018 - 2030 (USD Million)
  • Fig. 81 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 82 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 83 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 84 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 85 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 86 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 87 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Other Services, 2018 - 2030 (USD Million)
  • Fig. 88 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 89 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 90 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 91 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 92 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 93 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 94 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Other Services, 2018 - 2030 (USD Million)
  • Fig. 95 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 96 Global Biologics Regulatory Affairs Outsourcing, for Others Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 97 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 98 Global Biologics Regulatory Affairs Outsourcing, for Others Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 99 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 100 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 101 Global Biologics Regulatory Affairs Outsourcing, for Others Other Services, 2018 - 2030 (USD Million)
  • Fig. 102 Regional Outlook, 2023 & 2030
  • Fig. 103 North America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 US Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Canada Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Mexico Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Europe Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Germany Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 UK Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 France Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Italy Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Spain Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Denmark Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Sweden Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Norway Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Asia Pacific Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Japan Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 China Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 India Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Australia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 South Korea Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Thailand Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 Latin America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Brazil Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Argentina Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 126 Middle East and Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 South Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 128 Saudi Arabia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 129 UAE Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 130 Kuwait Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)